NCT03857477Active, not recruiting
The BARCODE 1 Study (Full Study): The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
The BARCODE 1 Study: The Use of Genetic Profiling to Guide Prostate Cancer Targeted Screening.
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
BARCODE 1 is a screening study designed to investigate the role of genetic profiling for targeting population prostate cancer screening. A pilot of 300 men were recruited aiming to inform the feasibility and accessibility of the study approach. The full study is an extension of the pilot study aiming to recruit a total of 5000 men.
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 4700 (actual)
- First submitted
- 26 Feb 2019
- Start date
- 14 Mar 2019
- Primary completion date
- 1 Apr 2024
- Lead sponsor
- Institute of Cancer Research, United Kingdom
- Diseases
- Prostate cancer
- NCT number
- NCT03857477
What you commit to
- Study type: Observational
- Participants enrolled: 4700
- From 14 Mar 2019 to the primary completion date, 1 Apr 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Previous diagnosis of cancer with a life-expectancy of less than five years.
- Previous diagnosis of prostate cancer.
Other illness
- Co-morbidities making prostate biopsy risk unacceptable (anticoagulants or antiplatelet medication including Warfarin, Clopidogrel, Apixaban, Dabigatran or other NOAC medications (Novel Oral Anti-Coagulant); poorly controlled diabetes, cardiovascular/respiratory disease, immunosuppressive medication or splenectomy).
- Contraindications to having an MRI (pacemakers, aneurysm clips, metallic cardiac valve/stent, Ventriculo-Peritoneal (VP) shunt, cochlear implant, neurotransmitter, metallic foreign bodies in eye(s), other metalwork, claustrophobia).
- Any significant psychological conditions that may be worsened or exacerbated by participation in the study.
Other
- Non-Caucasian ethnicity (including mixed race or Ashkenazi Jewish (excluded as these groups have different genetic risk profiles from those being studied).
- Negative prostate biopsy within one year before recruitment.
- Men with body mass index (BMI) 40 and above.
- Men with BMI 35 and above plus other co-morbidities.
Who the study is looking for
- Men aged 55 to 69 years.
- Caucasian ethnicity.
- WHO performance status 0-2.
- Absence of any psychological, familial, sociological or geographical situation potentially hampering compliance with the study protocol and follow-up schedule.
Age in the registry: 55 years to 69 years · Sex: Male · Accepts healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Institute of Cancer Research and Royal Marsden Hospital Coordinator of this site? Confirm its status | Sutton | United Kingdom | Unknown status |
Related publications
- The psychosocial impact of receiving a polygenic risk score informing risk of prostate cancer.Hered Cancer Clin Pract · 2026 · PMID 42458546
This page is information, not medical advice. Discuss any trial with your doctor.